Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 + Pembrolizumab in HNSCC
NCT03771820Phase 2Unknown
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of NK211 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by NanoCarrier Co., Ltd. Primary endpoints: Recommended Phase II Dose at 1 year and Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
NK211
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03771820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771820.